Landscape Capital Management’s Atrium Therapeutics RNA Stock Holding History

Landscape Capital Management’s Portfolio RNA Stock Details RNA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$167K	Buy	+20,158	New	+$238K	0.01%	555

Other funds holding RNA

Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return

Los Angeles Capital Management Los Angeles, California $29.2B AUM 33.64% 1-Year Est. Return

Squarepoint New York $90.8B AUM 26.98% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $85.7B AUM 51.02% 1-Year Est. Return

Trium Capital London, United Kingdom $79.4M AUM 36.67% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.32T AUM 44.66% 1-Year Est. Return

Bank of New York Mellon New York $608B AUM 32.77% 1-Year Est. Return

Nuveen Charlotte, North Carolina $420B AUM 34.97% 1-Year Est. Return

UBS Group Zurich, Switzerland $765B AUM 28.39% 1-Year Est. Return

AlphaCentric Advisors San Juan, Puerto Rico $113M AUM 27.37% 1-Year Est. Return

Landscape Capital Management's RNA Position: Q3 2026 in Review

Landscape Capital Management opened a new position in Atrium Therapeutics (RNA) in Q3 2026: 20,158 shares worth $167K. The stake represents 0.01% of the portfolio and ranks #555 among its holdings.

50 funds tracked by Wall St. Rank hold RNA as of Q3 2026.

Landscape Capital Management held 20,158 shares of Atrium Therapeutics worth $167K as of Q3 2026.
Atrium Therapeutics was a new Landscape Capital Management position in Q3 2026.
Atrium Therapeutics made up 0.01% of Landscape Capital Management's portfolio in Q3 2026, its #555 holding.
50 funds tracked by Wall St. Rank held Atrium Therapeutics as of Q3 2026.

Based on Landscape Capital Management's 13F filing for Q3 2026, filed 10 Nov 2026.